Trial assesses the impact of two immunomodulators in reducing CV risk among rheumatoid arthritis patients

People with rheumatoid arthritis are at increased risk of cardiovascular (CV) disease, with studies indicating an approximate 50 percent increase in risk of CV events such as heart attack and stroke.